Calithera Biosciences (CALA) Upgraded to Sell at ValuEngine
Calithera Biosciences (NASDAQ:CALA) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Tuesday.
Separately, Zacks Investment Research cut shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, July 10th. Three research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $16.50.
CALA traded down $0.10 during midday trading on Tuesday, hitting $5.35. 415,500 shares of the company traded hands, compared to its average volume of 456,566. The stock has a market capitalization of $196.13 million, a P/E ratio of -6.37 and a beta of 2.46. Calithera Biosciences has a 52 week low of $4.05 and a 52 week high of $18.35.
Institutional investors and hedge funds have recently bought and sold shares of the business. Sofinnova Ventures Inc bought a new position in Calithera Biosciences during the 1st quarter valued at about $126,000. Citigroup Inc. increased its position in shares of Calithera Biosciences by 78.4% during the 1st quarter. Citigroup Inc. now owns 23,746 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 10,433 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Calithera Biosciences during the 1st quarter valued at about $195,000. Alambic Investment Management L.P. purchased a new stake in shares of Calithera Biosciences during the 1st quarter valued at about $233,000. Finally, Alps Advisors Inc. increased its position in shares of Calithera Biosciences by 21.0% during the 1st quarter. Alps Advisors Inc. now owns 47,583 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 8,270 shares during the last quarter. Institutional investors and hedge funds own 54.85% of the company’s stock.
About Calithera Biosciences
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
Featured Article: What is the NASDAQ?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.